SCHEMBL4692926

SCHEMBL4692926

c1ccc2c(C3CN4CCC3CC4)occ2c1

nearest known ligand 0.51

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.51
CHRM2 P08172 2/20 0.51
CHRM4 P08173 2/20 0.51
CHRM5 P08912 2/20 0.51
CHRM1 P11229 2/20 0.51
CHRM3 P20309 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10899780 0.74 SIGMAR1 (0.37)
SCHEMBL4691735 0.72 CHRNA7 (0.56) CHRNA7CHRM2CHRM4CHRM5CHRM1
SCHEMBL9811962 0.71 TSHR (0.40)
SCHEMBL10900558 0.70 HTR2A (0.41) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL6645510 0.70 CDC25B (0.49) CHRNA7CHRM2CHRM4CHRM5CHRM1
SCHEMBL10903319 0.69 KCNH2 (0.46) CHRM1
SCHEMBL3217359 0.69 CHRNA7 (1.00) CHRNA7CHRM2CHRM4CHRM5CHRM1
SCHEMBL4689211 0.68 CHRNA7 (0.64) CHRNA7CHRM2CHRM4CHRM5CHRM1
SCHEMBL4692922 0.68 CHRM2 (1.00) CHRNA7CHRM2CHRM4CHRM5CHRM1
SCHEMBL8935488 0.67 CHRM5 (1.00) CHRNA7CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132704-A1 3-Substituted quinuclidines and their use PETERS DAN 2008-06-05 US disclosed
US-7332507-B2 3-substituted quinuclidines and their use NEUROSEARCH A/S (DK) 2008-02-19 US disclosed
EP-1339712-B1 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS NEUROSEARCH AS (DK) 2008-02-06 EP disclosed
EP-1513839-B1 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE NEUROSEARCH AS (DK) 2006-07-26 EP disclosed
US-20050176756-A1 3-Substituted quinuclidines and their use NEUROSEARCH A/S (DK) 2005-08-11 US disclosed
US-6884807-B2 3-substituted quinuclidines and their use as nicotinic agonists NEUROSEARCH, A/S (DE) 2005-04-26 US disclosed
EP-1513839-A1 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE NEUROSEARCH A/S (DK) 2005-03-16 EP disclosed
US-20040044026-A1 3-Substituted quinuclidines and their use as nicotinic agonists ANIONA APS (DK) 2004-03-04 US disclosed
WO-2003101987-A1 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE NEUROSEARCH A/S (DK) 2003-12-11 WO disclosed
EP-1339712-A1 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS NEUROSEARCH A/S (DK) 2003-09-03 EP disclosed
WO-2002044176-A1 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS NEUROSEARCH A/S (DK) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176756-A1 3-Substituted quinuclidines and their use CHRNA3, CHRNA5, CHRNA6 CHRNA7 6/4885CHRM2 20/4885CHRM4 19/4885
US-20040044026-A1 3-Substituted quinuclidines and their use as nicotinic agonists CHRNA3, CHRNA5, CHRNA7 CHRNA7 3/4885CHRM2 23/4885CHRM4 20/4885
US-20080132704-A1 3-Substituted quinuclidines and their use CHRNA3, CHRNA5, CHRM3 CHRNA7 8/4885CHRM2 20/4885CHRM4 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.